ResearchAndMarkets.com has added a report analyzing REBLOZYL sales, market size and commercial prospects through 2034. The assessment covers approved uses in beta-thalassemia and myelodysplastic syndromes, as well as potential opportunities in myelofibrosis and alpha-thalassemia, across the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. Growth drivers include REBLOZYL’s expansion into first-line treatment for anemia in adults with very low-, low- or intermediate-risk myelodysplastic syndromes requiring red blood cell transfusions. In the Phase III COMMANDS trial, 58.5% of patients receiving REBLOZYL achieved at least 12 weeks of red blood cell transfusion independence alongside a hemoglobin increase of at least 1.5 g/dL, compared with 31.2% for epoetin alfa. The report also examines physician adoption, clinical differentiation, regulatory approvals, geographic expansion, pricing, reimbursement, patent coverage, generic-entry risk and competition. In February 2026, Bristol Myers Squibb reported positive top-line results from the ex-US Phase II registrational study NCT05664737 of REBLOZYL, or luspatercept-aamt, versus placebo in adults with alpha-thalassemia. The report says this development may support lifecycle expansion, subject to complete study results and regulatory review.